BULLFROG AI HOLDINGS, INC. Stock-Based Compensation
BULLFROG AI HOLDINGS, INC. (BFRG) reported Stock-Based Compensation of $236.49 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $109.83K, a 38.26% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $126.66K, a 57.82% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $154.21K, a 28.03% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $378.23K, a 87.64% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.01M, a 7.10% increase from fiscal 2024.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $943.65K, a 49.42% increase from fiscal 2023.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $631.53K, a 85.66% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $340.15K, a 243.76% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $109.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $236.49K 10-Q · filed 2026-08-14 | $390.70K derived: sum of 3 quarters · filed 2026-08-14 | $768.93K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $126.66K 10-Q · filed 2026-05-14 | $280.86K derived: sum of 2 quarters · filed 2026-05-14 | $659.09K derived: sum of 3 quarters · filed 2026-05-14 | $837.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $154.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $532.44K derived: sum of 2 quarters · filed 2026-03-19 | $710.34K derived: sum of 3 quarters · filed 2026-08-14 | $1.01M 10-K · filed 2026-03-19 |
| 2025-09-30 | $378.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $556.13K derived: sum of 2 quarters · filed 2026-08-14 | $856.42K 10-Q · filed 2025-11-14 | $1.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $177.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $478.19K 10-Q · filed 2026-08-14 | $692.47K derived: sum of 3 quarters · filed 2026-08-14 | $894.04K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $300.29K 10-Q · filed 2026-05-14 | $514.57K derived: sum of 2 quarters · filed 2026-05-14 | $716.14K derived: sum of 3 quarters · filed 2026-05-14 | $908.52K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $214.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $415.85K derived: sum of 2 quarters · filed 2026-03-19 | $608.23K derived: sum of 3 quarters · filed 2026-03-19 | $943.65K 10-K · filed 2026-03-19 |
| 2024-09-30 | $201.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $393.95K derived: sum of 2 quarters · filed 2025-11-14 | $729.37K 10-Q · filed 2025-11-14 | $849.73K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $192.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $527.80K 10-Q · filed 2025-08-13 | $648.15K derived: sum of 3 quarters · filed 2025-08-13 | $769.62K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $335.42K 10-Q · filed 2025-05-13 | $455.77K derived: sum of 2 quarters · filed 2025-05-13 | $577.23K derived: sum of 3 quarters · filed 2025-05-13 | $839.50K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $120.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $241.82K derived: sum of 2 quarters · filed 2025-03-14 | $504.08K derived: sum of 3 quarters · filed 2025-03-14 | $631.53K 10-K · filed 2025-03-14 |
| 2023-09-30 | $121.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $383.73K derived: sum of 2 quarters · filed 2024-11-08 | $511.18K 10-Q · filed 2024-11-08 | $560.45K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $262.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $389.72K 10-Q · filed 2024-08-07 | $438.99K derived: sum of 3 quarters · filed 2024-08-07 | $490.53K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $127.45K 10-Q · filed 2024-05-10 | $176.73K derived: sum of 2 quarters · filed 2024-05-10 | $228.26K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $49.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $100.81K derived: sum of 2 quarters · filed 2024-03-29 | $340.15K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $51.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $290.88K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $239.34K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $98.95K 10-K · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |